AI MARKET SCANNING

Actinium Pharmaceuticals, Inc.

📅 Next Catalyst: Nov 12, 2026 (🌙 Close) 🏛️ NYSE American 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.35%
MAX GAP RECORD +8.66%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ATNM
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 12, 2026 Earnings Release 2026-11-12 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 07, 2026 Earnings Release 2026-08-07 (AFTER CLOSE)
+0.38%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
+0.82%
Nov 14, 2025 Earnings Release 2025-11-14 (AFTER CLOSE)
+8.66%
Aug 08, 2025 Earnings Release 2025-08-08 (AFTER CLOSE)
+0.65%
Mar 31, 2025 Earnings Release 2025-03-31 (AFTER CLOSE)
-0.62%
Nov 14, 2024 Earnings Release 2024-11-14 (AFTER CLOSE)
+0.61%
Aug 05, 2024 Earnings Release 2024-08-05 (AFTER CLOSE)
-4.84%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.1%
Bullish Gaps (2)
Bearish Gaps (2)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ATNM

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗